← Back to Cases
PMCPA Case

AUTH/3722/1/23: Complainant v Otsuka — Market research alleged to be disguised promotion (No breach after appeal)

📅 2023 | 🖉 Dr Anzal Qurbain
📊

Key facts

⌄
Case numberAUTH/3722/1/23
PartiesComplainant v Otsuka (Otsuka Europe Ltd)
IssueAllegations about market research (disguised promotion; patient record forms; approval/examination process)
Medicine referencedAbilify Maintena (aripiprazole) (brand tracking within atypical long-acting injectable antipsychotics)
Activity timeframeAnnual waves 2018–2021 (waves 1–4)
GeographyMulti-country including the UK (also Germany, France, Spain, Italy, Australia; Canada in waves 1–3)
Complaint received9 December 2022
Case completed24 April 2024
Panel outcomeNo breach for disguised promotion clauses; initially ruled breaches for high standards (approval/examination concerns) later appealed
Appeal outcomeAppeal successful; no breach of Clause 9.1 (2016), Clause 9.1 (2019) (x2), Clause 5.1 (2021)
Final outcomeNo breach of the Code

Download the full case report (PDF)

Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI
📋

What happened

⌄
  • An anonymous, contactable complainant (representing a group of employees/former employees) complained about annual “Awareness, Trial, and Usage (ATU)” tracking market research commissioned by Otsuka Europe Ltd and Lundbeck A/S, run annually 2018–2021 (waves 1–4) across multiple countries including the UK.
  • The complainant alleged the questionnaires repeatedly used the brand name “Abilify Maintena” and were therefore promotional/disguised promotion.
  • The complainant alleged the questionnaire content (including “patient record forms” asking HCPs to transcribe clinical record data for the last three patients) looked like a clinical study rather than market research.
  • The complainant alleged Otsuka Europe’s internal process lacked appropriate compliance “filtering”/review of the questionnaire and that affiliate compliance comments were not considered.
  • Otsuka said the research was legitimate brand tracking to understand market behaviour and inform business decisions; brand mentions were necessary, alongside competitors, and randomised; patient data was anonymised/aggregated and respondents were instructed not to provide identifiable information and to exclude patients in clinical trials.
  • Otsuka acknowledged the European Compliance team did not review the questionnaire as a matter of internal process, but said a signatory examined the materials; it also stated “minor changes” were agreed by email after approval.
  • The Panel initially ruled no breach for disguised promotion, but ruled breaches for “high standards” based on concern that materials may not have been examined in the final form used (given post-approval changes).
  • Otsuka appealed those “high standards” breach rulings; the Appeal Board considered additional detail about how post-approval changes were checked/approved by an appropriately qualified person (AQP) before use.
⚖️

Outcome

⌄
  • No breach overall (case outcome: NO BREACH OF THE CODE).
  • No Breach of Clause 9.1 (2016 Code) (Panel’s breach ruling overturned at appeal).
  • No Breach of Clause 12.2 (2016 Code).
  • No Breach of Clause 9.1 (2019 Code) (x2) (Panel’s breach ruling overturned at appeal).
  • No Breach of Clause 12.2 (2019 Code) (x2).
  • No Breach of Clause 5.1 (2021 Code) (Panel’s breach ruling overturned at appeal).
  • No Breach of Clause 25.4 (2021 Code).
  • Appeal: successful on all points raised by Otsuka.
🔒

Unlock the full case analysis

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value
£249/year
Annual — save £99
or
£29/mo
Monthly
Join Now — Instant Access
← All Cases Book a Free Compliance Call

⭐ Charter Member — Until 31 March

See the full compliance picture for every pharma company

291 Company Intelligence Reports — breach patterns, appeal history, industry ranking, PDF export. £1,999/year £2,499

Get Charter Access →

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week — free.

Subscribe Free